Bacterial Infections
Methodology & AI Transparency ⓘ
Bacterial Infections Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What are bacteria? Bacteria are tiny organisms (living things) that have only one cell.
- 2 Real-world patient consensus: Clinical coding for Bacterial Infections uses ICD-10 J09.9 across Infections & Antivirals specialty care.
- 3 Typical cash cost range: Differential triage of Bacterial Infections (J09.9) utilizes antimicrobial stewardship (narrow-spectrum in Bacterial Infections (J09.9: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Longitudinal Bacterial Infections monitoring tracks Complete Blood Count in Bacterial Infections (J09.9: (WBC & Differential)) toward WBC 4.0 – 10.0 x10^3/uL (J09.9).
Ask our AI Specialists anything about Bacterial Infections
What Is Bacterial Infections?
What are bacteria? Bacteria are tiny organisms (living things) that have only one cell. Under a microscope, they look like balls, rods, or spirals. They can be found almost everywhere on Earth. There are lots of bacteria in and on your body. In fact, your body has about 10 times more bacteria cells than human cells. There are many different types of bacteria. Most types don't make you sick. Some types are helpful. For example, "good" bacteria in your digestive system can help your body digest food and absorb vitamins and minerals . They can help protect you from getting sick. Bacteria are also used in making foods like yogurt and cheese.
Pathophysiology, Underlying Causes & Clinical Presentation
In Bacterial Infections (J09.9), physiological disruption stems from tissue neutrophil/lymphocyte recruitment [Bacterial Infections J09.9], Cross-referenced with NIH MeSH (Bacterial Infections), informing Bacterial, Viral & Fungal Infections protocols that track C-Reactive Protein / in Bacterial Infections (J09.9: Procalcitonin) (Resolution to baseline (J09.9)).
Common Symptoms & Clinical Signs
- • By touching surfaces or objects that have the bacteria on them and then touching your mouth, nose, or eyes
- • Through cuts, scrapes, and skin-to-skin contact with someone who has the infection
- • Presentation of Bacterial Infections (J09.9): regional lymph node in Bacterial Infections (J09.9: tenderness or acute)
- • Secondary Bacterial Infections clinical sign: acute fever, chills, in Bacterial Infections (J09.9: malaise, and myalgias)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Bacterial Infections Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | J09.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Bacterial Infections (J09.9: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (J09.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Bacterial Infections (J09.9: Procalcitonin) | Resolution to baseline (J09.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Bacterial Infections (J09.9: Culture & Sensitivity) | Pathogen clearance / negative test (J09.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Bacterial Infections
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Colistimethate Sodium Colistimethate Sodium Generic • RxCUI 1117522 | Polymyxin-class Antibacterial | 84% | $15.4867 | $ 185.00 /mo |
| Acetic Acid Aceticum Acidum, VoSol • RxCUI 197305 | Anti-bacterial Agent | 92% | $1.4376 | $ 17.60 /mo |
| Cefotaxime Claforan • RxCUI 309068 | Cephalosporin Antibacterial | 91% | $0.4200 | $ 25.51 /mo |
| Tinidazole Tindazole, Tindamax • RxCUI 199519 | Nitroimidazole Antimicrobial | 77% | $1.2526 | $ 50.38 /mo |
| Cefuroxime Sodium Cefuroxime Sodium Generic • RxCUI 1665444 | Cephalosporin Antibacterial | 86% | $0.2868 | $ 20.11 /mo |
| Ciprofloxacin HCl Ciloxan • RxCUI 309307 | Fluoroquinolone Antibacterial | 93% | $7.0048 | $ 10.12 /mo |
| Cefaclor Ceclor • RxCUI 197449 | Cephalosporin Antibacterial | 86% | $0.8733 | $ 18.35 /mo |
| Cefprozil Cefzil • RxCUI 197452 | Cephalosporin Antibacterial | 89% | $0.4814 | $ 13.15 /mo |
| Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Generic • RxCUI 310687 | Corticosteroid | 87% | $3.7744 | $ 161.36 /mo |
| Posaconazole Noxafil • RxCUI 1492043 | Azole Antifungal | 77% | $1.9969 | $ 40.79 /mo |
| Demeclocycline Hydrochloride Declomycin • RxCUI 905341 | Tetracycline-class Antimicrobial | 82% | $2.1230 | $ 50.21 /mo |
| Azithromycin Monohydrate Azasite, Zithromax • RxCUI 1668238 | Macrolide Antimicrobial | 83% | $3.5270 | $ 5.84 /mo |
| Metronidazole Vaginal Gel, 1.3 % Metronidazole Vaginal Gel, 1.3 % Generic • RxCUI 1608253 | Nitroimidazole Antimicrobial | 89% | $0.1839 | $ 15.95 /mo |
| Polymyxin B Sulfate Polymyxin B Sulfate Generic • RxCUI 204509 | Polymyxin-class Antibacterial | 76% | $0.4755 | $ 27.76 /mo |
| Posaconazole Delayed-Release Noxafil • RxCUI 1482908 | Azole Antifungal | 88% | $1.9969 | $ 40.79 /mo |
| Flucytosine Ancobon • RxCUI 197702 | Nucleoside Analog Antifungal | 76% | $3.2700 | $ 86.17 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bacterial Infections)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response: What a 1,313-Participant Study Found The E-R results support the MOV dose of 800 mg twice daily to treat COVID-19. Clinical pharmacology and therapeutics • 2023-06-15 • Phase III Randomized Trial | N = 1,313 | 96/100 | PMID 37017631 ↗ |
| Can This Approach Help? Inside the Latest Research on Gram-Negative Bacterial New England Journal of Medicine, Volume 395, Issue 17 , Page 1728-1743, October 29, 2026. New England Journal of Medicine • 2026-10-28 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 94/100 | PMID NEJM-106228020 ↗ |
| New Insights on Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute: What a 335-Participant Study Found TARGET demonstrated that ceftobiprole is noninferior to vancomycin/aztreonam in the treatment of ABSSSIs, in terms of early clinical response and investigator-assessed clinical success at the TOC visit. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2021-10-05 • Phase III Randomized Trial | N = 335 | 93/100 | PMID 32897367 ↗ |
| New Insights on Clinical and nutritional correlates of bacterial diarrhoea aetiology in young: What a 6,692-Participant Study Found The presence of MAM, dehydration or high stool frequency may be helpful in identifying children with MSD who might benefit from antibiotics. BMJ paediatrics open • 2024-04-11 • Phase III Randomized Trial | N = 6,692 | 90/100 | PMID 38604769 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of single-dose oral secnidazole for the treatment of trichomoniasis in Single-dose oral secnidazole 2 g was highly efficacious in curing trichomoniasis in women co-infected with BV. BMJ open • 2023-08-07 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37550019 ↗ |
Bacterial Infections Patient Community & “People Like Me” Threads
Filter Bacterial Infections community threads and patient logs by age, biological sex, dosage, and treatment duration.